BridgeMD
New treatment option for Thymic Carcinoma
Official title Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3)
ClinicalTrials.gov ID: NCT06402708
What this study is testing
What is Chemotherapy?
Chemotherapy is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for thymic carcinoma.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The goal of this clinical trial is to learn the role of adjuvant chemotherapy for patients with thymic carcinoma and completed resection. The main questions it aims to answer are: 1.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Voluntarily participate and sign an informed consent form in writing;
- Age range from 18 to 75 years old, regardless of gender;
- Within 3 months after the surgery is completed;
- Histologically diagnosed with thymic cancer;
- Complete resection based on surgical records, pathological reports, and postoperative imaging;
You likely can't join if
- Having a second primary tumor (excluding cured non malignant melanoma of the skin, papillary thyroid carcinoma, stage I seminomatoma, cervical...
- Symptomatic coronary heart disease, left heart failure, uncontrollable seizures, or loss of self-awareness due to mental illness;
- Pregnancy and lactation period;
- Patients with drug addiction, chronic alcoholism and AIDS;
- Researchers believe that participants are not suitable for this experiment.
See the full eligibility criteria
- Voluntarily participate and sign an informed consent form in writing;
- Age range from 18 to 75 years old, regardless of gender;
- Within 3 months after the surgery is completed;
- Histologically diagnosed with thymic cancer;
- Complete resection based on surgical records, pathological reports, and postoperative imaging;
- Masaoka stage: I-III
- No severe hematopoietic function, heart, lung, liver, kidney dysfunction, or immune deficiency;
- White blood cells ≥ 3 × 109/L; Neutrophils ≥ 1.5 × 109/L; Hemoglobin ≥ 10 g/dL; Platelets ≥ 100 × 109/L; Total bilirubin ≤ 1.5 times the upper limit of normal value; AST (SGOT)/ALT (SGPT) ≤ 2.5 times the upper limit of...
- Having a second primary tumor (excluding cured non malignant melanoma of the skin, papillary thyroid carcinoma, stage I seminomatoma, cervical carcinoma in situ, or other curable tumors that have been tumor free for...
- Symptomatic coronary heart disease, left heart failure, uncontrollable seizures, or loss of self-awareness due to mental illness;
- Pregnancy and lactation period;
- Patients with drug addiction, chronic alcoholism and AIDS;
- Researchers believe that participants are not suitable for this experiment.
The study team makes the final eligibility decision.
Where it's taking place
- Shanghai, Shanghai Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shanghai, Shanghai Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.